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Background. Glutamine metabolism is considered an important metabolic phenotype of proliferating tumor cells. Objective. The
objective of this study was to investigate the expression of glutamine metabolism-related and amino acid transporter proteins in
adrenal cortical neoplasms (ACNs) and pheochromocytomas (PCCs) in the adrenal gland. Methods. A tissue microarray was
constructed for 132 cases of ACN (115 cases of adrenal cortical adenoma and 17 cases of adrenal cortical carcinoma) and 189
cases of PCC. Immunohistochemical staining for glutamine metabolism-related proteins GLS1 and GDH and amino acid
transporter proteins SLC1A5, SLC7A5, and SLC7A11 as well as SDHB was performed and compared with clinicopathologic
parameters. Results. The expression levels of GLS (p < 0:001), SLC7A5 (p = 0:049), and SDHB (p = 0:007) were higher in ACN
than in PCC, whereas the expression levels of SLC1A5 (p < 0:001) and SLC7A11 (p < 0:001) were higher in PCC than in ACN.
In ACN, GLS positivity was associated with a higher Fuhrman grade (p = 0:009), and SLC1A5 positivity was associated with
SDHB positivity (p = 0:004) and a clear cell proportion < 25% (p = 0:010). SDHB negativity was also associated with tumor cell
necrosis (p = 0:007). In PCC, SLC7A11 positivity was associated with nonnorepinephrine type (p = 0:008). In Kaplan-Meier
analysis, patients with GLS positivity (p = 0:039) and SDHB negativity (p = 0:005) had significantly shorter overall survival in
ACN. In PCC patients with a GAPP score ≥ 3, GLS positivity (p = 0:001) and SDHB positivity (p = 0:001) were associated with
shorter disease-free survival, whereas GLS positivity (p = 0:004) was also associated with shorter overall survival. Conclusions.
The expression of glutamine metabolism-related and amino acid transporter proteins in ACN and PCC is distinct and
associated with prognosis.
1. Introduction
Typical tumors in the adrenal gland are adrenal cortical neo-
plasms (ACNs) arising from the adrenal cortex and pheo-
chromocytomas (PCCs) from the adrenal medulla. ACNs
comprise benign adrenal cortical adenomas (ACAs) and
malignant adrenal cortical carcinomas (ACCs). ACA is a rel-
atively common tumor, whereas ACC is an extremely rare
tumor with an annual incidence of 1–2 cases per 1 million
people with a highly aggressive phenotype [1, 2]. PCC is a
neuroendocrine tumor that occurs in the chromaffin cells of
the adrenal medulla, found in 2–8 cases per 1 million people
[3]. Although ACNs and PCCs can be differentiated by dis-
parities in the originating cells, histologic findings are similar
and the behavior of these tumors cannot be adequately
predicted based on histologic findings alone.
An important part of the metabolic pathway for tumor
maintenance and growth is glutamine metabolism and
amino acid transport. In cell culture and implanted tumor
studies, cancer cells were found to metabolize glutamine
better than other amino acids [4, 5]. Therefore, glutamine
metabolism is considered an important metabolic phenotype
of proliferating tumor cells. Glutamine metabolism contrib-
utes to two important factors in tumor cell proliferation:
the production of adenosine triphosphate (ATP) and supple-
mentation of intermediates for macromolecular synthesis.
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Proteins that play an important role in this glutamine meta-
bolic pathway are amino acid transporter-2 (ASCT2), which
is involved in the intracellular transport of glutamine con-
sumed by tumor cells, glutaminase 1 (GLS1), an enzyme that
converts glutamine to glutamate, and glutamate dehydroge-
nase (GDH), which converts glutamate into α-ketoglutarate
to affect the TCA cycle [6–8].
Amino acids are essential for the growth and survival
of tumor cells. Among them, essential amino acids such
as Thr, Met, Phe, Trp, Val, Ile, Leu, and Lys must be
obtained from outside the body, because they cannot be
synthesized internally [9–11]. In contrast, even though
nonessential amino acids can be synthesized within cells,
when their demand is significantly increased by proliferat-
ing tumor cells, additional supply is required from extra-
cellular spaces [12, 13]. Among various membrane-bound
solute carrier (SLC) transporters, SLC1, SLC3, SLC6,
SLC7, SLC15, SLC17, SLC18, SLC25, SLC26, SLC32,
SLC36, and SLC38 are involved in the transport of amino
acids. Although most amino acid transporters are
expressed in a tissue- and developmentally specific manner
in normal cells, the expression of specific amino acid
transporters is generally higher in tumor cells, depending
on the tumor type than in normal cells [9, 14–16].
Nonetheless, glutamine metabolism-related and amino
acid transporter proteins in ACNs and PCCs in the adrenal
gland have been poorly studied. The aim of this study was
to investigate the expression of glutamine metabolism-
related and amino acid transporter proteins in ACNs and
PCCs and to determine the clinical implications.
2. Materials and Methods
2.1. Patient Selection. Formalin-fixed paraffin-embedded sur-
gical tissue samples from patients diagnosed with ACN and
PCC were obtained from Severance Hospital from January
2000 to December 2012. All cases were retrospectively
reviewed by pathologists (Koo JS and Kim HM), and a histo-
logic evaluation was performed on hematoxylin-eosin-
(H&E-) stained slides. ACNs were examined using parame-
ters corresponding to the Weiss criteria [17, 18], and PCCs
and its catecholamine types were examined using parameters
of the GAPP scoring system [19]. Disease-free survival (DFS)
was calculated from the date of the first curative surgery to
the date of the first locoregional or systemic relapse, or death
without any relapse. Overall survival (OS) was estimated
from the date of the first curative operation to the date of
the last follow-up or death from any cause. Clinicopathologic
parameters evaluated in each tumor included patient age at
initial diagnosis, tumor recurrence, distant metastasis, and
patient survival. The study was approved by the Institutional
Review Board of Severance Hospital.
2.2. Tissue Microarray. Representative areas were selected on
H&E-stained slides, and a corresponding spot was marked
on the surface of the matching paraffin block. Core biopsies,
5mm each, were taken from selected areas and placed into a
5 × 4 recipient block. More than two tissue cores were
extracted from each case to minimize extraction bias. Each
tissue core was assigned a unique tissue microarray location
number that was linked to a database containing other
clinicopathologic data.
2.3. Immunohistochemistry. The information of antibodies
used for immunohistochemistry are listed in Supplementary
Table 1. Succinate dehydrogenase subunit B (SDHB) and
BCL2/adenovirus E1B 19kDa protein-interacting protein 3
(BNIP3) staining were also performed to assess SDHB
mutation and tumor hypoxia. Immunohistochemistry was
performed on formalin-fixed, paraffin-embedded tissue
sections using an automatic immunohistochemistry staining
device (Benchmark XT, Ventana Medical System, Tucson,
AZ, USA). Briefly, 5μm thick formalin-fixed paraffin-
embedded tissue sections were transferred to adhesive slides
and dried at 62°C for 30 minutes. Standard heat epitope
retrieval was performed for 30 minutes in ethylene diamine
tetraacetic acid, pH8.0, in an autotimer. The samples were
then incubated with primary antibodies. After incubation
with primary antibodies, the sections were incubated with
biotinylated anti-mouse immunoglobulins, peroxidase-
labeled streptavidin (LSAB kit, DakoCytomation), and 3,30-
diaminobenzidine. Negative control samples were processed
without the primary antibody. A positive control tissue was
used per the manufacturer’s recommendation. Slides were
counterstained with Harris hematoxylin.
2.4. Interpretation of Immunohistochemical Staining. All
immunohistochemical markers (GLS1, GDH, SLC1A5,
SLC7A5, SLC7A11, SDHB, and BNIP3) were accessed by
light microscopy. Expression of the included markers was
semiquantitatively evaluated using stained slides, as previ-
ously described [20]. Tumor cell staining was assessed using
the following criteria: 0, negative or weak immunostaining in
<1% of the tumor; 1, focal expression in 1–10% of tumors; 2,
positive in 11–50% of tumors; and 3, positive in 51–100% of
tumors. The entire area of each tumor was evaluated, and a
score of ≥2 determined by both pathologists was defined as
immunohistochemical staining positivity, whereas the score
of <2 was considered negativity.
2.5. Statistical Analysis. Data were analyzed using IBM SPSS
Statistics for Windows, Version 21.0 (Released 2012; IBM
Corp., Armonk, NY, USA). To determine the statistical sig-
nificance of differences, Student’s t-test and Fisher’s exact test
were used for continuous and categorical variables, respec-
tively. Statistical significance was set at p < 0:05. Kaplan-
Meier survival curves and log-rank statistics were employed
to evaluate the clinical significance of clinicopathologic
markers and the DFS and OS of the patients.
3. Results
3.1. Basal Characteristics of Patients. We included a total of
115 cases of ACA and 17 cases of ACC in this study. The
basal characteristics of these patients are presented in Supple-
mentary Table 2. Patient age (p = 0:048) and tumor size
(p < 0:001) were significantly different between the two
groups. Parameters comprising the Weiss criteria were also
significantly different between the two groups (all p < 0:001,
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Supplementary Table 2). One-hundred and eighty-nine cases
of PCC were included, and the basal characteristics of these
patients are presented in Supplementary Table 3.
3.2. Differential Expression of Glutamine Metabolism-Related
and Amino Acid Transporter Proteins, SDHB, and BNIP3 in
Adrenal Gland Neoplasms. GLS (p < 0:001), SLC7A5
(p = 0:007), SDHB (p < 0:001), and BNIP3 (p < 0:001) were
highly expressed in ACNs, whereas SLC1A5 (p = 0:049) and
SLC7A11 (p < 0:001) were highly expressed in PCCs
(Table 1). The heat map regarding the expression of immu-
nohistochemical markers and the representative images of
the antibody staining are shown in Figures 1 and 2. There
was no difference in the expression of glutamine
metabolism-related and amino acid transporter proteins
between ACAs and ACCs, and the expression of SDHB was
lower and BNIP3 was higher in ACCs (Table 2).
We divided our patients with PCC into the SDHB-
positive group and SDHB-negative group according to
SDHB positivity. Patients with SDHB positivity revealed to
have higher expression of GLS (p < 0:001), SLC1A5
(p = 0:014), and SLC7A11 (p = 0:001) compared to those
with SDHB negativity (Table 3).
3.3. Correlation between the Expression Levels of Glutamine
Metabolism-Related and Amino Acid Transporter Proteins
and SDHB with Clinicopathologic Factors. In ACN, GLS
positivity was associated with a higher Fuhrman grade
(p = 0:009), and SLC1A5 positivity was associated with
SDHB positivity (p = 0:004) and a clear cell proportion of <
25% (p = 0:010). Furthermore, SDHB negativity was associ-
ated with tumor cell necrosis (p = 0:007). In PCC, SLC7A11
positivity was associated with nonnorepinephrine-type
tumors (p = 0:008) (Figure 3).
3.4. Expression of Glutamine Metabolism-Related Proteins
and Amino Acid Transporter Proteins according to BNIP3.
Considering that tumor microenvironment could be related
Table 1: Expression of glutamine metabolism-related proteins and amino acid transporter proteins in adrenal gland neoplasm.
Parameters
Total
N = 321 (%)
Adrenal cortical neoplasm
n = 132 (%)
Pheochromocytoma
n = 189 (%) p value
GLS <0.001
Negative 248 (77.3) 85 (64.4) 163 (86.2)
Positive 73 (22.7) 47 (35.6) 26 (13.8)
GDH 0.956
Negative 316 (98.4) 130 (98.5) 186 (98.4)
Positive 5 (1.6) 2 (1.5) 3 (1.6)
SLC1A5 0.049
Negative 242 (75.4) 107 (81.1) 135 (71.4)
Positive 79 (24.6) 25 (18.9) 54 (28.6)
SLC7A5 0.007
Negative 316 (98.4) 127 (96.2) 189 (100.0)
Positive 5 (1.6) 5 (3.8) 0 (0.0)
SLC7A11 <0.001
Negative 259 (80.7) 126 (95.5) 133 (70.4)
Positive 62 (19.3) 6 (4.5) 56 (29.6)
SDHB <0.001
Negative 189 (58.9) 47 (35.6) 142 (75.1)
Positive 132 (41.1) 85 (64.4) 47 (24.9)
BNIP3 <0.001
Negative 293 (91.3) 111 (84.1) 182 (96.3)











Figure 1: Heat map of glutamine metabolism-related and amino acid transporter proteins found in adrenal gland neoplasms (ACA: adrenal
cortical adenoma; ACC: adrenal cortical carcinoma; PCC: pheochromocytoma).
3Disease Markers
to altered metabolism, we evaluated the expression of gluta-
mine metabolism-related proteins and amino acid trans-
porter proteins according to BNIP3 status. In ACN, BNIP3
positivity was associated with higher expression of GDH,
SLC1A5, SLC7A5, and SLC7A11 (p = 0:024, p = 0:002, p <
0:001, and p < 0:001). Meanwhile, BNIP3 positivity was asso-
ciated with the increased expression of GLS and GDH in
PCC (p = 0:008 and p = 0:003) (Table 4).
3.5. Impact of the Expression of Glutamine Metabolism-
Related and Amino Acid Transporter Proteins on Patient
Prognosis in Adrenal Gland Neoplasms. In Kaplan-Meier
analysis, patients with ACC had shorter DFS and OS com-
pared to ACA (all p < 0:001) (Supplementary Figure 1).
Additionally, GLS positivity (p = 0:039) and SDHB
negativity (p = 0:005) were associated with shorter OS in
ACNs. In a subgroup analysis of PCC patients with GAPP
score ≥ 3, GLS positivity (p = 0:001) and SDHB positivity
(p = 0:001) were associated with shorter DFS, whereas GLS
positivity (p = 0:004) was associated with shorter OS
(Figure 4).
4. Discussion
In the present study, we investigated the expression of gluta-
mine metabolism-related and amino acid transporter pro-
teins in ACNs and PCCs in the adrenal gland. Of note,
GLS, SLC7A5, and SDHB were highly expressed in ACNs,
and SLC1A5 and SLC7A11 were highly expressed in PCCs.
Glutamine metabolism and amino acid transport in adrenal
gland neoplasms have been rarely studied; therefore, it is dif-
ficult to compare our results with those of previous studies.
Several hypotheses could apply to the differential expres-
sion of glutamine metabolism-related and amino acid trans-
porter proteins in ACNs and PCCs. Generally, ACC is
detected using 18F-fludeoxyglucose (FDG) positron emission
tomography-computed tomography (PET-CT) and PCC by
18F-fluorodopa (18F-DOPA) PET-CT [21, 22]. 18F-FDG
PET-CT is used to detect glycolysis within a tumor, and gly-
colysis may be more active in ACNs than in PCCs because of
the higher expression levels of GLS1 in ACNs than PCCs.
Conversely, 18F-FDOPA is a fluorinated analog of the natu-
rally occurring amino acid L-DOPA. It is transported into a
cell by the amino acid transporter system L, which is com-
posed of CD98hc encoded by the SLC3A2 gene and LAT1
and LAT2 encoded by the SLC7A5 and SLC7A8 genes [23].
Therefore, the expression levels of amino acid transporter
proteins with similar functions, such as SLC1A5 and
SLC7A11, are higher in PCCs than in ACNs.
Previous studies have shown that nearly 40% of PCCs are
genetically inherited neoplasms, associated with unique met-
abolic abnormalities, oxygen sensing, hypermethylation,
DNA repair, upregulation of specific transporters and/or
receptors, and enzymes involved in the TCA cycle [24–28].
SDHx is a representative genetic variant commonly found
in PCCs, and mutations in SDHx result in abnormalities in
the TCA cycle that lead to altered metabolism [23, 29]. Sur-
prisingly, we found that SDHB positivity is associated with
GLS, SLC1A5, and SLC7A1 positivity in PCCs, and 75.9%
of patients were found to have SDHB negativity in immuno-
histochemical staining. Given that SDHB gene mutation is
present in approximately 6-9% of PCCs [30], this is rather
contradictory to the previous results that showed negative
staining for SDHB when SDHB mutation is present [31,
32]. Several possible explanations could be given regarding
this inconsistency. First, to minimize interobserver bias
between pathologists, we established a uniform standard to
define positivity of immunohistochemical staining, which
could have affected the interpretation of data. Second, SDHB
staining was performed by using commercial monoclonal











Figure 2: Expression of glutamine metabolism-related and amino
acid transporter proteins in adrenal gland neoplasms. The
expression of GLS, SLC7A5, and SDHB was higher in adrenal
cortical neoplasms, whereas the expression of SLC1A5 and
SLC7A11 was higher in pheochromocytomas.
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could have affected the immunohistochemical staining
results. Third, a difference of ethnicity and geographic differ-
ence could be present in pheochromocytoma. However, the
underlying cause of this discrepancy and its association with
the expression of glutamine metabolism-related and amino
acid transporter proteins should be further investigated.
Fuhrman grading is a well-known but poor prognostic
indicator in adrenal gland neoplasms [17, 18]. In this study,
GLS1 positivity was associated with higher Fuhrman grade
and poorer prognosis in both ACNs and PCCs. Because
tumor aggressiveness is associated with higher tumor meta-
bolic activity and the expression of glutamine metabolism-
related proteins, these findings imply that evaluation of
GLS1 positivity could provide useful information regarding
patient prognosis. However, we found that SDHB negativity,
which is known to be a negative prognostic factor in PCCs
[32], was associated with shorter OS in ACNs. Although
the discrepant finding that was found in our study could be
also related to the fact that we only included PCC with
GAPP score ≥ 3 in our analysis for prognostic factors, it is
also possible that the difference in defining SDHB positivity
could have affected the results.
The glutamine metabolism pathway could be a possible
target to control key enzymes and reduce glutamine uptake.
GLS1 inhibitors such as CB-839 [33, 34], BPTES [35–37],
and 968 [38–40] are currently in preclinical and clinical trials
for the treatment of various cancers. Further investigations
will be required to understand inhibition of GLS1 in adrenal
gland neoplasms, including the effect of glutaminemetabolism
Table 2: Expression of glutamine metabolism-related proteins and amino acid transporter proteins in adrenal cortical neoplasm.
Parameters
Total
N = 132 (%)
Adrenal cortical adenoma
n = 115 (%)
Adrenal cortical carcinoma
n = 17 (%) p value
GLS 0.110
Negative 85 (64.4) 77 (67.0) 8 (47.1)
Positive 47 (35.6) 38 (33.0) 9 (52.9)
GDH 0.114
Negative 130 (98.5) 114 (99.1) 16 (94.1)
Positive 2 (1.5) 1 (0.9) 1 (5.9)
SLC1A5 0.141
Negative 107 (81.1) 91 (79.1) 16 (94.1)
Positive 25 (5.9) 24 (20.9) 1 (5.9)
SLC7A5 0.124
Negative 127 (96.2) 112 (97.4) 15 (88.2)
Positive 5 (3.8) 3 (2.6) 2 (11.8)
SLC7A11 0.335
Negative 126 (95.5) 109 (94.8) 17 (100.0)
Positive 6 (4.5) 6 (5.2) 0 (0.0)
SDHB 0.007
Negative 47 (35.6) 36 (31.3) 11 (64.7)
Positive 85 (64.4) 79 (68.7) 6 (35.3)
BNIP3 <0.001
Negative 111 (84.1) 106 (92.2) 5 (29.4)
Positive 21 (15.9) 9 (7.8) 12 (70.6)
Table 3: Expression of glutamine metabolism-related proteins and




n = 142 (%)
SDHB positive
n = 47 (%) p value
GLS <0.001
Negative 130 (91.5) 33 (70.2)
Positive 12 (8.5) 14 (29.8)
GDH 0.153
Negative 141 (99.3) 45 (95.7)
Positive 1 (0.7) 2 (4.3)
SLC1A5 0.014
Negative 108 (76.1) 27 (57.4)
Positive 34 (23.9) 20 (42.6)
SLC7A5 n/a
Negative 142 (100.0) 47 (100.0)
Positive 0 (0.0) 0 (0.0)
SLC7A11 0.001
Negative 109 (76.8) 24 (51.1)
Positive 33 (23.2) 23 (48.9)
BNIP3 0.066
Negative 139 (97.9) 43 (91.5)


















































































Non-norepinephrine type Norepinephrine type
p = 0.007
p = 0.008
Figure 3: Correlation between the expression levels of glutamine metabolism-related and amino acid transporter proteins and
clinicopathologic factors. In adrenal cortical neoplasms, GLS positivity was associated with a higher Fuhrman grade, and SLC1A5
positivity was associated with SDHB positivity and a clear cell proportion < 25%. Furthermore, SDHB negativity was associated with
tumor cell necrosis. In pheochromocytomas, SLC7A11 positivity was associated with nonnorepinephrine types of tumors.
Table 4: Expression of glutamine metabolism-related proteins and amino acid transporter proteins according to BNIP3 status in adrenal
gland neoplasm.
Parameters
Adrenal cortical neoplasm Pheochromocytoma
BNIP3 negative
n = 111 (%)
BNIP3 positive
n = 21 (%) p value
BNIP3 negative
n = 182 (%)
BNIP3 positive
n = 7 (%) p value
GLS 0.080 0.008
Negative 75 (67.6) 10 (47.6) 160 (87.9) 3 (42.9)
Positive 36 (32.4) 11 (52.4) 22 (12.1) 4 (57.1)
GDH 0.024 0.003
Negative 111 (100.0) 19 (90.5) 181 (99.5) 5 (71.4)
Positive 0 (0.0) 2 (9.5) 1 (0.5) 2 (28.6)
SLC1A5 0.002 0.410
Negative 95 (85.6) 12 (57.1) 131 (72.0) 4 (57.1)
Positive 16 (14.4) 9 (42.9) 51 (28.0) 3 (42.9)
SLC7A5 <0.001 n/a
Negative 111 (100.0) 16 (76.2) 182 (100.0) 7 (100.0)
Positive 0 (0.0) 5 (23.8) 0 (0.0) 0 (0.0)
SLC7A11 <0.001 0.425
Negative 111 (100.0) 15 (71.4) 129 (70.9) 4 (57.1)
Positive 0 (0.0) 6 (28.6) 53 (29.1) 3 (42.9)
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inhibition in ACNs, which show high glutamine metabolic
activity. Alternatively, experimental evidence suggests that
inhibition of amino acid transporters halts the growth of can-
cer cells and promotes cancer cell death [41–43]. For example,
the SLC1A5 inhibitor benzylserine (Benser) hampers the pro-







































































































































Figure 4: Impact of the expression of glutamine metabolism-related and amino acid transporter proteins on the prognosis of patients with
adrenal gland neoplasms. In a univariate analysis, shorter overall survival was associated with GLS positivity (p = 0:039) and SDHB negativity
(p = 0:005) in adrenal cortical neoplasms. In a subgroup analysis of PCC patients with GAPP scores ≥ 3, GLS positivity (p = 0:001) and SDHB
positivity (p = 0:001) were associated with shorter disease-free survival in univariate analysis, whereas GLS positivity (p = 0:004) was
associated with shorter overall survival.
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melanoma cell lines [44, 45]. A selective SLC7A5 inhibitor,
JPH203, has been shown to suppress cancer cell growth. In
addition, JPH203 did not affect normal cells in vivo, suggest-
ing that it can be used as a treatment agent [46, 47].
The advantage of this study is that it is the first to evaluate
markers associated with glutamine metabolism in a large
number of pathologically confirmed adrenal gland neoplasm,
which is rare. However, this study also has several limita-
tions. First, the expression of glutamine metabolism-related
and amino acid transporter proteins was evaluated using
TMA samples. In particular, as SDHB immunohistochemical
staining, but not SDHB gene expression, was used to divide
patients with PCC, this could have affected the interpretation
of the results. Furthermore, the adoption of different cut-off
to define SDHB immunohistochemical staining positivity
and negativity compared to the previous studies [32, 48]
should be also taken into account. Second, the clinical char-
acteristics of neoplasms in the study were assessed retrospec-
tively and genetic status could not be evaluated. Third, the
number of ACC cases included in ACNs was small, and the
heterogeneity of tumors included might have influenced the
results. Finally, because tumor hypoxia is a factor related to
altered glutamine metabolism, the changes in the tumor
microenvironment could be also related to the expression
of glutamine metabolism-related proteins and amino acid
transporter proteins investigated.
Taken together, the expression of glutamine metabolism-
related and amino acid transporter proteins is distinct
between ACNs and PCCs and is associated with prognosis.
Targeting glutamine metabolism-related and amino acid
transporter proteins may hold potential therapeutic value
for adrenal gland neoplasms.
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